Ladanyi, Marc

Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy

Elkrief, A., Méndez-Salazar, E. O., Maillou, J., Vanderbilt, C. M., Gogia, P., Desilets, A., Messaoudene, M., Kelly, D., Ladanyi, M., Hellmann, M. D., et al. (2024) · npj Precision Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 68

Plasma DNA-Based Molecular Diagnosis, Prognostication, and Monitoring of Patients With EWSR1 Fusion-Positive Sarcomas

Shukla, N. N., Patel, J. A., Magnan, H., Zehir, A., You, D., Tang, J., Meng, F., Samoila, A., Slotkin, E. K., Ambati, S. R., et al. (2017) · JCO Precision Oncology

Sarcoma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 52

Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers

Drilon, A., Schoenfeld, A. J., Arbour, K. C., Litvak, A., Ni, A., Montecalvo, J., Yu, H. A., Panora, E., Ahn, L., Kennedy, M., et al. (2019) · Molecular Case Studies

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 31

Abstract 99: Evolution of OncoKB, a precision oncology knowledgebase

Suehnholz, S. P., Kundra, R., Zhang, H., Smith, S., Nissan, M., Yao, Y., LaFave, L., Gala, K., Miles, L., Arcila, M. E., et al. (2021) · Cancer Research

Cancer Genomics and DiagnosticsGenomics and Rare Diseases

Cited by 3

RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236

Pfeil, A. J., Zhang, T., Cheng, R., Mattar, M. S., Gomez Marti, J. L., Gili, L., Lai, R., Khodos, I., Master, R. P., Dix, J.-M., et al. (2025) · Clinical Cancer Research

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 3